Imlygic (talimogene laherparepvec): Special considerations to minimize the potential occurrence of adverse events in HSV-1 seronegative patients receiving vials from affected lots: Injections from Imlygic 106 PFU/mL vials from the affected lot numbers ...

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Imlygic
Active substance
talimogene laherparepvec
Therapeutic area (MeSH)
Melanoma
Procedure number
EMEA/H/C/002771
Regulatory outcome
Variation
DHPC type
  • Adverse event
  • Quality defect
Human ATC code
L01XX51
Dissemination date
16/06/2022

How useful was this page?

Add your rating